This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
SLAMF9 / SLAM family member 9 · IHC design guide
Design Immunohistochemistry for SLAMF9
Plan chromogenic SLAMF9 IHC with the catalog antibody starting at 2.5 μg/mL (datasheet). Assess the reported cytoplasmic tissue staining (HPA tissue IHC) alongside the expected membrane location (UniProt), and interpret staining cautiously given its poor concordance with RNA expression (HPA tissue IHC).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
SLAMF9 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Cytoplasmic tissue staining (HPA tissue IHC); membrane expected (UniProt) | |
| Staining pattern | General cytoplasmic staining in tissue cells (HPA tissue IHC) | |
| Antigen retrieval | Citrate pH 6.0 HIER, 95–98 °C, 20 min (rule: cytoplasmic / membrane antigen) | |
| Positive control | Adrenal gland+4 more · see all | |
| Negative control | Adipose tissue+4 more · see all |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep fixation consistent across paraffin sections. (standard IHC practice; not target-specific) | |
| Caveat | Very low consistency between staining and RNA expression (HPA tissue IHC) | |
| Regulation | Predominantly hematopoietic expression (UniProt) | |
| Isoform / epitope | 2 isoforms; map the epitope to the extracellular or cytoplasmic region (UniProt) |
Section 1
Recommended SLAMF9 IHC & IF Protocols
The catalog antibody IHC-P protocol is followed by 4 published SLAMF9 IHC protocols from target-verified articles (PMC8688141; PMC6145869; PMC11297030; PMC12885906).
| Sample | Tissue sections; selected-image fixative not specified (standard IHC workflow) |
| Fixation | Image fixative and duration unreported (datasheet A13838); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat-induced epitope retrieval in citrate buffer, pH 6.0, 20 min at 95–98 °C (standard rule: cytoplasmic / membrane antigen) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% normal serum of the secondary host, 30 min, room temperature (standard) |
| Primary antibody | Rabbit anti-SLAMF9, 2.5 μg/mL (datasheet A13838) |
| Primary incubation | Overnight at 4 °C (standard) |
| Detection | HRP-polymer secondary, DAB chromogen 5–10 min (standard) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | SLAMF9-positive staining in glandular cells of adrenal gland (HPA tissue IHC: Medium). HPA tissue profile: General cytoplasmic expression. No signal in the no-primary control. |
💡Decision noteStart with citrate pH 6.0 HIER at 95–98 °C for 20 min (page antigen retrieval). EDTA at 100 °C for 20 min is a published alternative (PMC8688141 methods).
Section 2
What Is the Expected SLAMF9 Staining Pattern?
SLAMF9 is a membrane protein with an extracellular region at residues 19–236 and a cytoplasmic tail at 258–289 (UniProt Q96A28: topology). Immune cells, including monocytes and dendritic cells, are plausible cells to examine (UniProt Q96A28: tissue specificity). Treat any IHC pattern as provisional: HPA reports general cytoplasmic staining, RNA as not detected, and tissue IHC reliability as uncertain (HPA: tissue IHC).
| Immune cells show a distinct cell-edge signal in a chromogenic paraffin section. | This is compatible with membrane localisation (UniProt Q96A28: topology). Record which cells stain and compare with local controls; morphology alone does not establish SLAMF9 identity (general IHC practice). HPA has not established a reliable membrane pattern by tissue IHC (HPA: Uncertain). |
| Staining is predominantly cytoplasmic, with little visible cell-edge enrichment. | HPA describes general cytoplasmic expression, but rates its tissue IHC uncertain because antibody staining and RNA expression have very low consistency (HPA: tissue IHC). Since UniProt places SLAMF9 at the membrane, treat cytoplasmic staining as unresolved and check another validated approach before assigning localisation (UniProt Q96A28: subcellular location; general IHC practice). |
| Strong nuclear staining appears without a corresponding cell-edge signal. | A nuclear-only pattern conflicts with the annotated membrane location and transmembrane segment at 237–257 (UniProt Q96A28: topology). Consider nonspecific staining or a detection artefact; assess negative controls and cell morphology before calling the section positive (general IHC practice). |
| Adipocytes or other unexpected cells stain as strongly as the cells under study. | HPA reports SLAMF9 as not detected in adipocytes, although its tissue IHC reliability is uncertain (HPA: adipose tissue; HPA: Uncertain). Such staining warrants checks for cross-reactivity and endogenous detection activity; it does not, by itself, prove either cause (general IHC practice). |
| Color is spread across tissue, empty spaces, or the section edge. | A diffuse deposit that does not follow cell boundaries is difficult to interpret as membrane staining (UniProt Q96A28: membrane; general IHC practice). Compare a negative reagent control and inspect background across the whole section before scoring individual cells (general IHC practice). |
💡Expected SLAMF9 appearanceA credible positive is a distinguishable, cell-edge signal in morphologically identified immune cells (UniProt Q96A28: membrane and tissue specificity), while widespread nuclear or cell-free color raises concern for artefact (general IHC practice); intensity has no established target-specific threshold because HPA tissue IHC is uncertain (HPA: Uncertain).
| Cell compartment and epitope | SLAMF9 has an extracellular region at 19–236, a membrane span at 237–257, and a cytoplasmic tail at 258–289 (UniProt Q96A28: topology). The supplied sources do not locate the catalog antibody's epitope, so they cannot predict which processing condition exposes it (UniProt Q96A28: topology; supplied record). |
| Strength of tissue evidence | HPA rates tissue IHC Uncertain, citing very low consistency between antibody staining and RNA expression, and lists RNA specificity as not detected (HPA: tissue IHC). Its reported positive cells are observations to investigate, rather than validated positive controls (HPA: tissue IHC). |
| Choice of candidate tissue and cell | HPA reports low staining in lung macrophages and not detected staining in lymph-node germinal-center cells (HPA: tissue IHC). UniProt describes expression in several immune-cell classes but reports no expression in peripheral blood leukocytes (UniProt Q96A28: tissue specificity). Specify the cell population when interpreting a section. |
| Antibody validation and target variation | The listed HPA antibody, HPA035153, has Uncertain IHC status and no reported ICC status (HPA: antibodies). UniProt lists 2 isoforms (UniProt Q96A28: isoforms); the supplied sources do not establish whether an antibody detects both. Interpret a negative result within that validation limit. |
| Situation | Likely cause | Next action |
|---|---|---|
| No signal appears in a section that previously stained with the same assay. | A failed run or a change in specimen or reagent handling is possible (general IHC practice). HPA supplies no dependable strongly positive SLAMF9 tissue control (HPA: Uncertain; HPA: tissue IHC). | Run the previously confirmed control alongside the sample; verify detection reagents, retrieval conditions, and antibody dilution against the assay record before interpreting absence of staining (general IHC practice). |
| Only diffuse cytoplasmic staining appears. | HPA reports a general cytoplasmic profile, but its IHC evidence is uncertain (HPA: tissue IHC); UniProt assigns SLAMF9 to the membrane (UniProt Q96A28: subcellular location). | Record the pattern as unresolved, inspect cell edges at higher magnification, and compare negative controls or an independently validated antibody if available (general IHC practice). |
| Unexpected cell populations stain strongly. | Cross-reactivity or endogenous detection activity may contribute (general IHC practice). HPA tissue calls alone cannot validate the identity of stained cells here (HPA: Uncertain). | Confirm cell identity by morphology, include an appropriate negative reagent control, and investigate endogenous activity relevant to the chosen chromogenic detection system (general IHC practice). |
| Background obscures cell boundaries. | Nonspecific binding or incomplete control of endogenous detection activity can produce background in chromogenic IHC (general IHC practice). | Check the negative control, blocking and wash steps, and detection-system controls; optimise conditions against a reproducible reference section before scoring localisation (general IHC practice). |
| The signal changes when antigen retrieval conditions change. | Retrieval conditions can affect staining in paraffin IHC generally (general IHC practice). Target-specific fixation sensitivity or an optimal SLAMF9 retrieval condition is not reported in the supplied sources (UniProt Q96A28; HPA: tissue IHC). | Compare conditions on matched sections with the same controls and record both signal and background; do not infer SLAMF9-specific epitope masking from this comparison alone (general IHC practice). |
| Can IF/ICC confirm the IHC result? | HPA summarises SLAMF9 as membrane-localised but provides no ICC-IF image cell lines; its listed antibody has no ICC status (HPA: subcellular; HPA: antibodies). | Treat IF/ICC as a separate validation question and consult the dedicated IF/ICC guide; do not present the HPA summary as image-based confirmation of this paraffin IHC pattern (HPA: subcellular). |
Experiment evidence
IHC & IF images showing SLAMF9 staining
A13838 · IHCImmunohistochemistry of SLAMF9 in human kidney tissue with SLAMF9 antibody at 2.5 μg/mL.
A13838 · IFImmunofluorescence of SLAMF9 in human kidney tissue with SLAMF9 antibody at 20 μg/mL.
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000162723-SLAMF9/tissue/cerebral+cortex#imid_8688916
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000162723-SLAMF9/tissue/colon#imid_8666522
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000162723-SLAMF9/tissue/liver#imid_8666523
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000162723-SLAMF9/tissue/kidney#imid_8666508
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for SLAMF9 IHC & IF
🧪Run adrenal gland first and look for staining in glandular cells (HPA: Medium in adrenal gland glandular cells). Use adipose tissue adipocytes as the negative comparison (HPA: Not detected in adipocytes); on the adrenal slide, use non-glandular areas at background as an internal reference, without treating them as a validated negative cell population (HPA: adrenal gland row reports glandular cells only).
Positive control tissue: Adrenal gland (Glandular cells, HPA Medium)
Negative control tissue: Adipose tissue (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA carries no ICC-IF cell line for SLAMF9; derive a cell-line control from the positive tissue's cell type (Glandular cells) and confirm it by RNA or western blot first.
Technical controls: Include no-primary or secondary-only and host- and clonality-matched isotype controls, plus a SLAMF9 knockout sample or peptide competition if a suitable blocking peptide is available (standard IHC control practice). For chromogenic staining, block endogenous peroxidase and assess tissue background before scoring adrenal gland signal (standard IHC practice).
⚠️Feasibility: A target-specific fixation window or fixation effect is unreported, and the A13838 kidney IHC caption gives 2.5 μg/mL but does not report a fixative (selected-SKU tissue-IHC caption). Antigen-retrieval dependence is unreported; optimize retrieval using the positive and negative tissues together (supplied evidence; standard IHC practice). The evidence does not establish that frozen sections or IF are easier; check adrenal tissue for pigment and autofluorescence that could obscure weak signal (standard IHC/IF practice).
HPA tissue IHC evidence for SLAMF9
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Uncertain — Very low consistency between antibody staining and RNA expression data.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adrenal gland | Glandular cells | Medium | Protein (IHC) | HPA → |
| Appendix | Glandular cells | Medium | Protein (IHC) | HPA → |
| Breast | Glandular cells | Medium | Protein (IHC) | HPA → |
| Bronchus | Respiratory epithelial cells | Medium | Protein (IHC) | HPA → |
| Caudate | Neuronal cells | Medium | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | Adipocytes | Not detected | Protein (IHC) | HPA → |
| Epididymis | Glandular cells | Not detected | Protein (IHC) | HPA → |
| Fallopian tube | Glandular cells | Not detected | Protein (IHC) | HPA → |
| Heart muscle | Cardiomyocytes | Not detected | Protein (IHC) | HPA → |
| Lymph node | Germinal center cells | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced SLAMF9 IHC Tips
Troubleshoot SLAMF9 chromogenic IHC by checking retrieval, compartment, cell identity and control staining before interpreting signal intensity.
Which retrieval condition should I start with for SLAMF9 in paraffin sections?
Start with citrate buffer at pH 6.0, heated to 95–98 °C for 20 min (page retrieval setting). Keep section thickness, cooling time and detection conditions matched while comparing retrieved sections, so a change in signal can be assigned to retrieval (standard IHC practice). If staining remains weak, test an alternative retrieval buffer on adjacent sections as a fallback, alongside the original citrate condition (standard IHC practice). Check whether stronger retrieval improves membrane-associated staining without increasing diffuse cytoplasmic or tissue-edge signal; SLAMF9 is annotated as a membrane protein (UniProt Q96A28 topology), while the reported tissue-IHC pattern is generally cytoplasmic and uncertain (HPA: tissue IHC).
How should I troubleshoot variable SLAMF9 staining after fixation?
Target-specific fixation sensitivity is unknown: the selected kidney IHC caption gives no fixative, and the supplied evidence provides no SLAMF9 fixation comparison (A13838 caption; supplied evidence). For paraffin IHC, document the fixative and fixation duration for each specimen, then compare sections processed under matched conditions (standard IHC practice). If fixation history varies, run those specimens in the same staining batch with a documented control section rather than attributing intensity differences to SLAMF9 expression (standard IHC practice). Review tissue preservation and retrieval consistency before changing antibody concentration; the selected image reports 2.5 µg/mL but does not establish performance across fixation conditions (A13838 caption).
Should I score cytoplasmic staining as SLAMF9 positive?
SLAMF9 has an extracellular region at residues 19–236, one transmembrane segment at 237–257 and a cytoplasmic tail at 258–289 (UniProt Q96A28 topology). Assess membrane-associated signal separately from diffuse cytoplasmic signal, using the same scoring rules across sections (UniProt Q96A28 topology; standard IHC practice). The tissue-IHC profile describes general cytoplasmic expression, but its reliability is uncertain because staining and RNA data have very low consistency (HPA: tissue IHC). Require appropriate control staining and convincing cellular morphology before assigning diffuse cytoplasmic chromogen to SLAMF9; record mixed patterns rather than combining them into one positive score (standard IHC practice).
Could isoforms or epitope location explain discordant SLAMF9 staining?
SLAMF9 has 2 annotated isoforms and glycosylation sites at residues 99 and 208 (UniProt Q96A28). The supplied antibody evidence does not map its epitope or establish which isoforms it recognizes, so an isoform-specific explanation for staining differences remains untested (supplied evidence). Request the antibody's immunogen or epitope information before interpreting signal as extracellular or cytoplasmic, then check whether that region is shared by the isoforms (standard IHC practice; UniProt Q96A28 topology). Compare serial sections under matched retrieval and detection conditions; a change in staining alone cannot identify an isoform or demonstrate an effect of glycosylation (standard IHC practice).
How can IF help assess the cells and compartments stained in SLAMF9 IHC?
On a separate IF section, multiplex SLAMF9 with a validated marker for the immune-cell population being assessed; monocytes, dendritic cells, and B and T cells appear in the SLAMF9 expression record (UniProt Q96A28 tissue specificity; standard IF practice). Select a fluorophore in a channel with low tissue autofluorescence and include unstained and single-channel controls before interpreting colocalisation (standard IF practice). If the antibody binds the extracellular region, assess staining without permeabilisation first; an epitope on the cytoplasmic tail requires access through the membrane (UniProt Q96A28 topology; standard IF practice). Because the supplied evidence does not map this antibody's epitope or provide IF validation, establish those properties before using IF to adjudicate the IHC pattern (supplied evidence).
What should I check when SLAMF9 chromogen appears widespread?
Check a no-primary control for nonspecific detection and endogenous peroxidase activity, and include a peroxidase-blocking step before DAB development (standard chromogenic IHC practice). Keep primary-antibody exposure, wash conditions and DAB development time matched while adjusting one variable at a time (standard IHC practice). The selected kidney image used 2.5 µg/mL antibody, but its caption does not define a working range for other sections or processing conditions (A13838 caption). Treat widespread cytoplasmic color cautiously: HPA reports a general cytoplasmic profile with uncertain reliability and very low agreement with RNA expression data (HPA: tissue IHC).
How should I quantify SLAMF9 staining when positive cells are sparse? ⚠ ANSWER MARKED FOR VERIFICATION
Define the cell population and compartment before scoring, and report membrane-associated and cytoplasmic staining separately (UniProt Q96A28 topology; standard IHC practice). For an intensity-based readout, calculate an H-score from the percentage of cells at intensities 0–3, yielding a possible range of 0–300 (standard IHC practice). For sparse positive cells, also report percentage positive among the specified viable cell population or positive-cell density per mm² of evaluable tissue (standard IHC practice). Apply one threshold across matched sections, exclude damaged or necrotic areas, and retain the cell-population denominator because immune-cell abundance can change the apparent tissue-level signal (standard IHC practice; UniProt Q96A28 tissue specificity).
What distinguishes credible SLAMF9 staining from artefact in paraffin IHC?
Give greatest weight to reproducible staining in intact, identifiable cells with a membrane-associated component, consistent with SLAMF9's annotated topology (UniProt Q96A28 topology; standard IHC practice). Check the stained cell population against the documented immune-cell expression context, while recognising that peripheral blood leukocytes were reported without expression in the supplied record (UniProt Q96A28 tissue specificity). Discount signal limited to section edges, necrotic areas or a no-primary control, and investigate residual endogenous peroxidase when DAB appears without primary antibody (standard IHC practice). Do not treat the reported general cytoplasmic tissue pattern as independent confirmation: HPA rates its reliability uncertain and reports very low staining-to-RNA consistency (HPA: tissue IHC).
Boster reagents
Best SLAMF9 / SLAM family member 9 IHC Antibodies
A13838 has IHC and IF images from human kidney tissue (catalog image captions). Its listed reactivity includes human, mouse and rat (catalog reactivity).
Real IHC data
Anti-SLAM family member 9 SLAMF9 Antibody
Cat # A13838
A13838 is listed for IHC-P and shows SLAMF9 staining in human kidney tissue at 2.5 μg/mL (catalog applications; IHC image caption). A13838 is also listed for IF and shows human kidney staining at 20 μg/mL (catalog applications; IF image caption).
Which to pick: Choose A13838 for paraffin-section IHC: IHC-P is listed, and its own IHC caption documents human kidney staining; the fixative is unreported (catalog applications; IHC image caption). For fluorescence, A13838 has a human kidney IF image, but ICC validation is unreported (catalog applications; IF image caption). A13838 lists human, mouse and rat reactivity; its supplied IHC and IF images document human tissue only (catalog reactivity; image captions).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry Q96A28 (SLAF9_HUMAN, SLAM family member 9).
- Human Protein Atlas. SLAMF9 tissue IHC expression (reliability: Uncertain).
- Human Protein Atlas. SLAMF9 subcellular location (ICC-IF): Membrane.
- Human Protein Atlas. SLAMF9 antibody validation summary (1 antibodies).
- Single-cell transcriptomic landscapes of a rare human laryngeal chondrosarcoma. Journal of cancer research and clinical oncology 2022 — PMC8688141.
- The novel immunoglobulin super family receptor SLAMF9 identified in TAM of murine and human melanoma influences pro-inflammatory cytokine secretion and migration. Cell death & disease 2018 — PMC6145869.
- The prognostic and immune significance of SLAMF9 in pan-cancer and validation of its role in colorectal cancer. Scientific reports 2024 — PMC11297030.
- Macrophage-associated SLAMF9 is a potential therapeutic target for glioma. Translational cancer research 2026 — PMC12885906.
- PubMed PMID:11300479 — UniProt-cited evidence.
- PubMed PMID:11685473 — UniProt-cited evidence.
- PubMed PMID:12975309 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for SLAMF9 (SLAM family member 9). Expected localisation Cytoplasmic tissue staining (HPA tissue IHC); membrane expected (UniProt). Antigen retrieval: Citrate pH 6.0 HIER, 95–98 °C, 20 min (rule: cytoplasmic / membrane antigen). Validated IHC antibody: A13838 at 2.5 μg/mL (the product's own IHC validation image is shown). Controls (HPA): positive Adrenal gland (Glandular cells); negative Adipose tissue. IHC workflow; specimen preparation unspecified. Protocol steps: 1. Sample: Tissue sections; selected-image fixative not specified (standard IHC workflow); 2. Fixation: Image fixative and duration unreported (datasheet A13838); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat-induced epitope retrieval in citrate buffer, pH 6.0 , 20 min at 95–98 °C…; 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% normal serum of the secondary host, 30 min , room temperature (standard); 8. Primary antibody: Rabbit anti-SLAMF9, 2.5 μg/mL (datasheet A13838); 9. Primary incubation: Overnight at 4 °C (standard). Watch for: Fixation: Keep fixation consistent across paraffin sections. (standard IHC practice; not target-specific); Caveat: Very low consistency between staining and RNA expression (HPA tissue IHC); Isoform / epitope: 2 isoforms; map the epitope to the extracellular or cytoplasmic region (UniProt); Regulation: Predominantly hematopoietic expression (UniProt). Evidence: UniProt Q96A28, HPA tissue IHC · Uncertain, HPA ICC-IF · Membrane, Datasheet A13838, PMC8688141, PMC6145869. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/SLAMF9/immunohistochemistry-ihc-guide.